SCHEMBL2247681

SCHEMBL2247681

CC(C)(Cc1ccc(F)cc1)N(C(=O)c1ccc(-c2cccc(Cl)c2)cc1)[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 4/20 0.45
MMP2 P08253 4/20 0.45
MMP8 P22894 4/20 0.45
ADAMTS5 Q9UNA0 1/20 0.45
MMP9 P14780 2/20 0.39
MMP13 P45452 2/20 0.39
MMP3 P08254 1/20 0.39
MMP10 P09238 1/20 0.39
MME P08473 6/20 0.38
MMEL1 Q495T6 4/20 0.38
SLC6A7 Q99884 1/20 0.37
ACE P12821 2/20 0.37
FFAR1 O14842 1/20 0.37
C3AR1 Q16581 1/20 0.36
RORC P51449 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
CCKBR P32239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245198 0.94 MMP12 (0.40) MMP12MMP2MMP8ADAMTS5MMP9
SCHEMBL2254232 0.92 MMP12 (0.47) MMP12MMP2MMP8ADAMTS5MMP13
SCHEMBL2242485 0.91 MMP2 (0.45) MMP12MMP2MMP8ADAMTS5MME
SCHEMBL2248055 0.90 MMP2 (0.42) MMP12MMP2MMP8ADAMTS5MMP3
SCHEMBL2249890 0.90 MMP12 (0.48) MMP12MMP2MMP8ADAMTS5MMP9
SCHEMBL2248769 0.89 MMP12 (0.44) MMP12MMP2MMP8ADAMTS5MMP13
SCHEMBL4356632 0.87 MMP12 (0.39) MMP12MMP2MMP8ADAMTS5MME
SCHEMBL2247909 0.87 RXRA (0.45) MMP12MMP2MMP8ADAMTS5FFAR1
SCHEMBL4364281 0.86 MMP12 (0.46) MMP12MMP2MMP8ADAMTS5MME
SCHEMBL2247710 0.86 ADAMTS5 (0.38) MMP12MMP2MMP8ADAMTS5MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP12 54/4885MMP2 49/4885MMP8 70/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP12 54/4885MMP2 49/4885MMP8 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.